Shots:

• The BTD is based on a P-II trial evaluating D-PLEX100 vs SOC alone in 201 patients for the prevention of SSIs in abdominal colorectal surgery
• The results demonstrated a significant decrease in SSIs of 59 % in the ITT population and a decrease of 69% in the Per Protocol population
• The ongoing P-III studies in abdominal surgery- SHIELD I and SHIELD II are on track. D-PLEX100 has received two FDA’s FTD for the prevention of post-abdominal surgery incisional infections and for the prevention of sternal wound infections post-cardiac surgery- as well as two QIDP's in the same indications

 ­ Ref: PRNewswire | Image: PRNewswire